RxDoctor Payments Data

Shauna Snitko, PA

Medical · Providence, RINPI 1962647065

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $376 and has fallen 81.4% since, to $70 in 2025.

$835in general payments, 2019–2025

Across 34 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tolmar, Inc.$127
  • Antares Pharma, Inc.$87
  • Halozyme Inc$82
  • 180 Medical, Inc.$79
  • AbbVie$76
  • Laborie Medical Technologies Corp.$59
  • plus $325 from 9 others

What the payments were for

  • Food & beverage$835100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$835 in reported general payments places this provider in the 60th percentile of 77 medical providers in Rhode Island.

See all medical providers in Rhode Island

Medicare billing

Part B allowed, 2024
$106,263
Medicare patients
607
Services billed
3,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron192$148,033
MyrbetriqMirabegron155$113,527
Mirabegron ErMirabegron27$15,105
Tamsulosin Hcl758$13,864
Solifenacin Succinate208$9,047
Testosterone78$7,915
Methenamine Hippurate109$6,947
Trospium Chloride ErTrospium Chloride26$5,120
Alfuzosin Hcl ErAlfuzosin Hcl210$4,978
Finasteride269$4,515
Dutasteride83$3,748
Potassium Citrate ErPotassium Citrate63$3,715
Cefpodoxime Proxetil67$2,691
Trimethoprim63$2,479
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl17$2,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$27$148,033192 claims
Astellas Pharma US IncMyrbetriq$40$113,527155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 77 medical providers in Rhode Island.

Other medical in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →